Leukotriene modifiers as potential therapeutics for cardiovascular disease.
about
Differential induction of BLT receptor expression on human endothelial cells by lipopolysaccharide, cytokines, and leukotriene B4Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cellsCoactosin-like protein supports 5-lipoxygenase enzyme activity and up-regulates leukotriene A4 productionThe immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptorsThe role of lipoxygenases in pathophysiology; new insights and future perspectives5-Lipoxygenase pathway in experimental abdominal aortic aneurysmsAbdominal aortic aneurysm: novel mechanisms and therapiesEnhanced expressions and activations of leukotriene C4 synthesis enzymes in D-galactosamine/lipopolysaccharide-induced rat fulminant hepatic failure modelStructure and inhibition of mouse leukotriene C4 synthaseThe leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field.5-Lipoxygenase Gene Variants Are Not Associated With Atherosclerosis or Incident Coronary Heart Disease in the Multi-Ethnic Study of Atherosclerosis CohortCommon polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease.Electrophilic fatty acid species inhibit 5-lipoxygenase and attenuate sepsis-induced pulmonary inflammation.Potent and selective inhibitors of human reticulocyte 12/15-lipoxygenase as anti-stroke therapiesDiet-gene interactions and PUFA metabolism: a potential contributor to health disparities and human diseases.Genetic Variants in the FADS Gene: Implications for Dietary Recommendations for Fatty Acid Intake.Synthesis of 11-thialinoleic acid and 14-thialinoleic acid, inhibitors of soybean and human lipoxygenasesPotential role of the lipoxygenase derived lipid mediators in atherosclerosis: leukotrienes, lipoxins and resolvins.Anti-inflammatory therapies for cardiovascular diseaseBiological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.Overview of recent drug discovery approaches for new generation leukotriene A4 hydrolase inhibitors.Cysteinyl leukotriene signaling aggravates myocardial hypoxia in experimental atherosclerotic heart diseaseIncreased expression of leukotriene C4 synthase and predominant formation of cysteinyl-leukotrienes in human abdominal aortic aneurysmNovel proresolving and tissue-regenerative resolvin and protectin sulfido-conjugated pathwaysExpression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability.5-(4-Hydroxy-2,3,5-trimethylbenzylidene) thiazolidine-2,4-dione attenuates atherosclerosis possibly by reducing monocyte recruitment to the lesion.Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention.Cysteinyl leukotriene type I receptor desensitization sustains Ca2+-dependent gene expression.Structure and ligand based drug design strategies in the development of novel 5- LOX inhibitors.Endothelial cysteinyl leukotriene 2 receptor expression mediates myocardial ischemia-reperfusion injury.Expression, purification and crystallization of human 5-lipoxygenase-activating protein with leukotriene-biosynthesis inhibitors.A Case of Pranlukast-Induced Anaphylactic Shock.Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers.Isotope sensitive branching and kinetic isotope effects in the reaction of deuterated arachidonic acids with human 12- and 15-lipoxygenasesThe potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field.A novel synthetic route to 3-sulfenyl- and 3-selenylindoles by n-Bu4NI-induced electrophilic cyclizationTranscellular biosynthesis of cysteinyl leukotrienes in vivo during mouse peritoneal inflammation.Synthesis of 3-sulfenyl- and 3-selenylindoles by the Pd/Cu-catalyzed coupling of N,N-dialkyl-2-iodoanilines and terminal alkynes, followed by n-Bu(4)NI-induced electrophilic cyclization.Dual 12/15- and 5-lipoxygenase deficiency in macrophages alters arachidonic acid metabolism and attenuates peritonitis and atherosclerosis in ApoE knock-out mice.Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway.
P2860
Q24543690-10876A21-F810-47E1-A032-5DE2123D0762Q24546541-1DDAF3D4-8F3D-4B0B-AF66-8A6A3FEFBECAQ24678254-E33A365D-61E9-486C-B113-3E36CE09A6B7Q24681206-578B5FD0-59FB-4AB7-A75D-54BAB827314EQ26795652-64730731-32DE-4199-9DA0-C417C996B033Q27342659-632D3159-6ADE-4130-AFE0-A5D6437A18F6Q28087319-E8B763E1-C688-439E-8CFB-051389C4554CQ28279233-FD3C5527-AB64-43E3-A39F-5840D9150633Q28538615-C52ABC48-7E8B-4038-B96E-C65668521084Q30234961-0F7292D9-FB4C-4115-B9A4-CDA076C3AEE0Q30277078-CA2EE236-6CCB-4F19-81ED-5B0BCADDA18BQ33622665-194E53C2-A306-4E71-B8AD-6D08E1C5999BQ33632763-EE559580-58C5-494F-8AE2-C89FE07567BCQ33662463-22CFD354-776E-4571-85AD-F83F11A0D820Q33702786-249C7E60-FADC-451A-816E-0078B743346DQ33805039-85B85C23-5D27-4131-B40C-6710DD2BE159Q33903800-B0241565-FBBB-43B5-B0B8-2E541C04D9A1Q34113615-45097189-C4CD-421E-86CA-0E3A21A8B4F0Q34137872-18D8C733-9825-487A-9259-FB84A349A6EFQ34245387-34653A2E-1C60-4376-A92B-E7B79E521020Q34308008-06CDFFC9-48DC-4D2C-BB49-E3D1C973455DQ34359022-D96DABAF-8532-49C5-8175-152DEB8FB8B8Q34397052-2DF4573C-B694-40B0-968A-1AD7F3968B8BQ34464346-D12974C8-61CD-4B8D-B4FB-161AAD34123FQ34601356-ACBCC36B-1816-4E6D-A52B-1F9251C0591EQ35216398-A0678E03-4A46-4EE0-B696-157909D6DE5FQ35597223-97F18F5D-BD16-4813-A884-BBFE3E744D5AQ35738041-CAEC11AD-87B1-46EB-AB6B-3307BFE2C5ECQ36345885-546F0252-EB40-4A2A-9867-A3EDFA7B504EQ36482287-D361F9BA-9C65-4B62-9967-1D5C232E1304Q36591781-40ADB202-EAC6-444F-BF97-A3F606FCC6C2Q36636612-0F4EE315-BCD7-4EFD-BDCF-D92A944AA600Q36775615-AADED3C4-8365-45BF-94B6-2E01395F104CQ36952303-930A7571-78E4-4C34-B098-B64FAABD561FQ37016080-99413A5A-73A1-4006-8768-1357D8420D7AQ37073644-59D88867-6EEA-44A4-BB25-F2C1BB43BC47Q37208628-6C11C30F-2E41-46FB-8266-3FF710A8346DQ37326620-CF297E8F-1F28-4F84-AADD-F6CC59C727FFQ37344116-F19E6DE6-B479-4CC6-987D-14EDF6D39593Q37349830-C9C30E48-8EA9-4C5C-9DF6-5EAB5F02D44E
P2860
Leukotriene modifiers as potential therapeutics for cardiovascular disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Leukotriene modifiers as potential therapeutics for cardiovascular disease.
@ast
Leukotriene modifiers as potential therapeutics for cardiovascular disease.
@en
type
label
Leukotriene modifiers as potential therapeutics for cardiovascular disease.
@ast
Leukotriene modifiers as potential therapeutics for cardiovascular disease.
@en
prefLabel
Leukotriene modifiers as potential therapeutics for cardiovascular disease.
@ast
Leukotriene modifiers as potential therapeutics for cardiovascular disease.
@en
P356
P1476
Leukotriene modifiers as potential therapeutics for cardiovascular disease.
@en
P2093
Colin D Funk
P2888
P304
P356
10.1038/NRD1796
P577
2005-08-01T00:00:00Z